Janbain M - Search Results

1

Real-world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non-interventional, post-authorization safety study.

Tarantino MD, Hardesty B, Metjian A, Ortel TL, Chen J, Badejo K, Ma A, Cuker A, Rajasekhar A, Friedman KD, Janbain M. Tarantino MD, et al. Among authors: janbain m. Haemophilia. 2023 Sep;29(5):1259-1268. doi: 10.1111/hae.14832. Epub 2023 Aug 16. Haemophilia. 2023. PMID: 37584309

2

Bortezomib in plasmablastic lymphoma: a case report and review of the literature.

Saba NS, Dang D, Saba J, Cao C, Janbain M, Maalouf B, Safah H. Saba NS, et al. Among authors: janbain m. Onkologie. 2013;36(5):287-91. doi: 10.1159/000350325. Epub 2013 Apr 5. Onkologie. 2013. PMID: 23689224 Review.

3

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors.

Chai-Adisaksopha C, Nevitt SJ, Simpson ML, Janbain M, Konkle BA. Chai-Adisaksopha C, et al. Among authors: janbain m. Cochrane Database Syst Rev. 2017 Sep 25;9(9):CD011441. doi: 10.1002/14651858.CD011441.pub2. Cochrane Database Syst Rev. 2017. PMID: 28944952 Free PMC article. Review.

4

Design of the HEM-POWR study: a prospective, observational study of real-world treatment with damoctocog alfa pegol in patients with haemophilia A.

Sanabria M, Álvarez Román MT, Castaman G, Janbain M, Matsushita T, Meijer K, Oldenburg J, Friedl S, Reding MT. Sanabria M, et al. Among authors: janbain m. BMJ Open. 2021 Sep 2;11(9):e044997. doi: 10.1136/bmjopen-2020-044997. BMJ Open. 2021. PMID: 34475142 Free PMC article.

5

Interim analyses of the multinational real-world prospective cohort HEM-POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A.

Reding MT, Álvarez-Román MT, Castaman G, Janbain M, Matsushita T, Meijer K, Schmidt K, Oldenburg J. Reding MT, et al. Among authors: janbain m. Eur J Haematol. 2024 Feb;112(2):286-295. doi: 10.1111/ejh.14114. Epub 2023 Oct 24. Eur J Haematol. 2024. PMID: 37876046

6

Acquired hemophilia A: emerging treatment options.

Janbain M, Leissinger CA, Kruse-Jarres R. Janbain M, et al. J Blood Med. 2015 May 8;6:143-50. doi: 10.2147/JBM.S77332. eCollection 2015. J Blood Med. 2015. PMID: 26056504 Free PMC article. Review.

7

Use of Factor XIII (FXIII) concentrate in patients with congenital FXIII deficiency undergoing surgical procedures.

Janbain M, Nugent DJ, Powell JS, St-Louis J, Frame VB, Leissinger CA. Janbain M, et al. Transfusion. 2015 Jan;55(1):45-50. doi: 10.1111/trf.12784. Epub 2014 Jul 29. Transfusion. 2015. PMID: 25070582

8

What is the role of an extended half-life product in immune tolerance induction in a patient with severe hemophilia A and high-titer inhibitors?

Janbain M, Pipe S. Janbain M, et al. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):648-649. doi: 10.1182/asheducation-2016.1.648. Hematology Am Soc Hematol Educ Program. 2016. PMID: 27913541 Free PMC article. Review.

9

Cancer of the Indiana Pouch: a case report and review of the literature.

Saba N, Saba J, Janbain M, Bitar C, Lipsky A, Blaya M. Saba N, et al. Among authors: janbain m. Clin Genitourin Cancer. 2013 Dec;11(4):e30-4. doi: 10.1016/j.clgc.2013.07.001. Epub 2013 Sep 27. Clin Genitourin Cancer. 2013. PMID: 24075928 No abstract available.

10

Protein S antibody as an adjunct therapy for hemophilia B.

Wilson HP, Pierre A, Paysse AL, Kumar N, Cooley BC, Rudra P, Dorsey AW, Polania-Villanueva D, Chatterjee S, Janbain M, Velez MC, Majumder R. Wilson HP, et al. Among authors: janbain m. Blood Adv. 2024 Jan 23;8(2):441-452. doi: 10.1182/bloodadvances.2023010819. Blood Adv. 2024. PMID: 37773781 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

17 results

Search Page